Anti-Aging Gene to Rewind a Heart's Age

Unveiling the Potential: Can an Anti-Aging Gene Rewind a Heart’s Age?

This Anti-Aging Gene Can Turn Back Your Heart’s Clock by Years! 🕰️✨

In a ground-breaking finding, scientists have discovered an anti-aging gene common in centenarians that can astonishingly slow down the biological age of the heart by ten years. The work, which was published in Cardiovascular Research, clarifies the remarkable advantages of this gene as well as how it might be used to address the unmet therapeutic need of delaying the aging process of the heart.

The Fountain of Youth in Our Genes:

The ageing heart undergoes a natural decline in function and perfusion that conventional treatments struggle to halt. However, carriers of a healthy mutant gene, often found in centenarians and individuals from ‘blue zone’ regions known for longevity, exhibit a different narrative. These individuals not only live to 100 years or more but also maintain good health and show resistance to cardiovascular complications associated with aging.

Protecting the Heart: A Genetic Gift:

Scientists believe that the identified gene plays a pivotal role in safeguarding the heart against aging-related diseases, such as heart failure. Paolo Madeddu, a professor of experimental cardiovascular medicine, highlights the varying rates of harmful changes in heart function among individuals due to factors like lifestyle choices and genetic inheritance. The study explores how the gene helps to maintain a youthful heart by shielding it from the adverse effects of aging.

The Therapeutic Potential of LAV-BPIFB4:

Carriers of a longevity-associated variant (LAV) of the BPIFB4 gene demonstrate prolonged health spans and reduced cardiovascular complications. Supplementation of LAV-BPIFB4 through gene therapy proves beneficial in improving cardiovascular performance in various models, including limb ischemia, atherosclerosis, and diabetes. The study aims to address the pressing need to delay the heart’s spontaneous aging, especially in the context of ischaemic heart failure.

Cardiac Rejuvenation Unveiled:

Immunohistological studies on hearts from elderly patients with ischemic heart failure reveal a remarkable reduction in vessel coverage by pericytes. However, patients with the homozygous LAV-BPIFB4 genotype show attenuation of this defect. The administration of the anti-aging gene not only halts the decay of heart function in middle-aged mice but also rewinds the heart’s biological clock by more than 10 years in elderly mice, showcasing its potential for cardiac rejuvenation.

Hope for Heart Failure Patients:

The breakthrough presents a promising target for patients with heart failure, offering the possibility of transferring the healthy gene from centenarians to unrelated individuals for heart protection. The study’s first author, Monica Cattaneo, emphasizes the positive impact on pericytes, stating that the addition of the longevity gene leads to cardiac rejuvenation, making the cells more efficient in constructing new blood vessels.

Looking to the Future:

The researchers express optimism about the broader implications of their findings, suggesting a potential new wave of treatments inspired by the genetics of centenarians. While acknowledging that this is early-stage research, Professor James Leiper, associate medical director at the British Heart Foundation, anticipates a revolutionary approach to treating heart failure and preventing its development in the first place.

The results of the study provide hope for reversing the deterioration of heart function in older people by utilizing a healthy gene present in centenarians. As the investigation continues, there is optimism that this genetic finding may result in revolutionary heart failure therapies, moving us closer to understanding the mechanisms underlying aging and improving cardiovascular health.

References:

Quail D.F., Joyce J.A. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31:326–341. doi: 10.1016/j.ccell.2017.02.009. – DOI – PMC – PubMed

Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. – DOI – PubMed

Lawless C, Wang C, Jurk D, Merz A, Zglinicki T, Passos JF. Quantitative assessment of markers for cell senescence. Exp Gerontol 2010;45:772–778.